• linkedin
  • Increase Font
  • Sharebar

    Water vapor ablation yields positive results at 2 years

    BPH patients show improved IPSS, BPH impact index scores vs. medical monotherapy


    Better IPSS improvement at 2 years

    In looking at the outcomes, patients treated with the Rezum System showed greater improvement in IPSS and BPH impact index than those receiving the alpha-blocker at 2 years. In addition, Rezum appeared to result in a greater maximum flow rate (Qmax) than alpha-blockers, but this didn’t reach statistical significance and there was no clear pattern that emerged when comparing post-void residual volume.

    Read: OTC alpha-blocker use feasible

    When comparing Rezum and the 5-alpha-reductase inhibitor cohort, Rezum showed significantly greater improvements in IPSS and BPH impact index than the 5-alpha-reductase inhibitor over 2 years, Dr. Gupta said. When comparing Rezum with combination medical therapy, IPSS and BPH impact index were similar at 2 years. Rezum improved Qmax as versus combination therapy at 1 year, with medical therapy catching up at 24 months. Combination therapy improved post-void residual volume to a greater extent than Rezum, he added.

    “Though flow rate and short-term symptom improvement are encouraging, 3-, 5-, and 10-year data will dictate whether the procedure will remain a part of the urologist’s armamentarium,” Dr. Gupta said.

    One of Dr. Gupta’s co-authors is an investigator and meeting participant/lecturer for NxThera, Inc. Several study co-authors have a financial and/or other relationship with one or more pharmaceutical companies.

    More from Urology Times:

    5-ARI use does not raise erectile dysfunction risk

    Data cast light on ED/5-ARI connection

    Physician employment: Both good and bad results

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    Aine Cryts
    Aine Cryts is a freelancer based in Boston. She is a frequent contributor to Managed Healthcare Executive on topics such as diabetes, ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available